FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1592-1598 June 3, 1993 Number 22 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Hepatic veno-occlusive disease and idiopathic interstitial pneumonitis are major causes of morbidity and mortality after bone marrow transplantation. Fibrosis is a characteristic of both conditions, and transforming growth factor (TGF) has been implicated in the pathogenesis of fibrosis.

Methods Using acid-ethanol extraction to remove TGF from human plasma and a mink-lung epithelial-cell growth-inhibition assay to measure TGF activity, we quantified plasma TGF in 10 normal subjects and 41 patients before and after they underwent high-dose chemotherapy and autologous bone marrow transplantation for advanced breast cancer.

Results There was no difference in pretransplantation TGF levels between the controls and the patients who did not have hepatic veno-occlusive disease or idiopathic interstitial pneumonitis after transplantation. In contrast, pretransplantation TGF levels were significantly higher in patients in whom hepatic veno-occlusive disease or idiopathic interstitial pneumonitis developed than in the controls or the patients without these conditions. The predictive value for the development of either condition was 90 percent or more when pretransplantation plasma TGF levels were more than 2 SD above the mean established in the controls.

Conclusions The plasma TGF concentration measured after induction chemotherapy but before high-dose chemotherapy and autologous bone marrow transplantation strongly correlates with the risk of hepatic veno-occlusive disease and idiopathic interstitial pneumonitis after these treatments.

Source Information

From the Department of Radiation Oncology (M.S.A., H.R., R.L.J.) and the Department of Medicine, Division of Hematology-Oncology (W.P. Peters, W.P. Petros), Duke University Medical School, Durham, N.C.

Address reprint requests to Dr. Jirtle at Box 3433, Duke University Medical Center, Durham, NC 27710.

Full Text of this Article

This article has been cited by other articles:

• Sugaru, E., Sakai, M., Horigome, K., Tokunaga, T., Kitoh, M., Hume, W. E., Nagata, R., Nakagawa, T., Taiji, M. (2005). SMP-534 inhibits TGF-{beta}-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Am. J. Physiol. Renal Physiol. 289: F998-F1004 [Abstract] [Full Text]  
• Elliott, R. L., Blobe, G. C. (2005). Role of Transforming Growth Factor Beta in Human Cancer. JCO 23: 2078-2093 [Abstract] [Full Text]  
• Muraoka-Cook, R. S., Kurokawa, H., Koh, Y., Forbes, J. T., Roebuck, L. R., Barcellos-Hoff, M. H., Moody, S. E., Chodosh, L. A., Arteaga, C. L. (2004). Conditional Overexpression of Active Transforming Growth Factor {beta}1 In vivo Accelerates Metastases of Transgenic Mammary Tumors. Cancer Res. 64: 9002-9011 [Abstract] [Full Text]  
• Bartram, U., Speer, C. P. (2004). The Role of Transforming Growth Factor {beta} in Lung Development and Disease. Chest 125: 754-765 [Abstract] [Full Text]  
• Laping, N. J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J. F., Olson, B. A. (2002). Inhibition of Transforming Growth Factor (TGF)-beta 1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF-beta Type I Receptor Kinase Activity: SB-431542. Mol. Pharmacol. 62: 58-64 [Abstract] [Full Text]  
• Anscher, M. S., Marks, L. B., Shafman, T. D., Clough, R., Huang, H., Tisch, A., Munley, M., Herndon, J. E. II, Garst, J., Crawford, J., Jirtle, R. L. (2001). Using Plasma Transforming Growth Factor Beta-1 During Radiotherapy to Select Patients for Dose Escalation. JCO 19: 3758-3765 [Abstract] [Full Text]  
• Coker, R K, Laurent, G J, Jeffery, P K, du Bois, R M, Black, C M, McAnulty, R J (2001). Localisation of transforming growth factor {beta}1 and {beta}3 mRNA transcripts in normal and fibrotic human lung. Thorax 56: 549-556 [Abstract] [Full Text]  
• Yong, S.-J., Adlakha, A., Limper, A. H. (2001). Circulating Transforming Growth Factor-{beta}1 : A Potential Marker of Disease Activity During Idiopathic Pulmonary Fibrosis. Chest 120: 68S-70S [Full Text]  
• Blobe, G. C., Schiemann, W. P., Lodish, H. F. (2000). Role of Transforming Growth Factor {beta} in Human Disease. NEJM 342: 1350-1358 [Full Text]  
• McCormick, L. L., Zhang, Y., Tootell, E., Gilliam, A. C. (1999). Anti-TGF-{beta} Treatment Prevents Skin and Lung Fibrosis in Murine Sclerodermatous Graft-Versus-Host Disease: A Model for Human Scleroderma. J. Immunol. 163: 5693-5699 [Abstract] [Full Text]  
• MOZES, M. M., BÖTTINGER, E. P., JACOT, T. A., KOPP, J. B. (1999). Renal Expression of Fibrotic Matrix Proteins and of Transforming Growth Factor-{beta} (TGF-{beta}) Isoforms in TGF-{beta} Transgenic Mice. J. Am. Soc. Nephrol. 10: 271-280 [Abstract] [Full Text]  
• Arsalane, K., Dubois, C. M., Muanza, T., Bégin, R., Boudreau, F., Asselin, C., Cantin, A. M. (1997). Transforming Growth Factor-beta 1 Is a Potent Inhibitor of Glutathione Synthesis in the Lung Epithelial Cell Line A549: Transcriptional Effect on the GSH Rate-limiting Enzyme gamma -Glutamylcysteine Synthetase. Am. J. Respir. Cell Mol. Bio. 17: 599-607 [Abstract] [Full Text]  
• Border, W. A., Noble, N. A. (1994). Transforming Growth Factor {beta} in Tissue Fibrosis. NEJM 331: 1286-1292 [Full Text]